Literature DB >> 25447850

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

K Rajender Reddy1, Kimberly L Beavers2, Sarah P Hammond3, Joseph K Lim4, Yngve T Falck-Ytter5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25447850     DOI： 10.1053/j.gastro.2014.10.039

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  161 in total

Review 1.  Management of hepatitis B in special populations.

Authors:  Kali Zhou; Norah Terrault
Journal:  Best Pract Res Clin Gastroenterol       Date:  2017-06-08       Impact factor: 3.043

2.  Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.

Authors:  Arpan Patel; Suna Yapali; Anna S F Lok
Journal:  Hepatol Int       Date:  2015-08-14       Impact factor: 6.047

Review 3.  Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.

Authors:  Tiffany Wu; Ryan M Kwok; Tram T Tran
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

Review 4.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

Review 5.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

6.  Letters to the Editor.

Authors:  Tarik Akar; Gökhan Dindar
Journal:  Ochsner J       Date:  2015

Review 7.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

8.  HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use.

Authors:  Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

9.  Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.

Authors:  Jessica P Hwang; Maria E Suarez-Almazor; Scott B Cantor; Andrea Barbo; Heather Y Lin; Sairah Ahmed; Mariana Chavez-MacGregor; Christian Donato-Santana; Cathy Eng; Alessandra Ferrajoli; Michael J Fisch; Peter McLaughlin; George R Simon; Gabriela Rondon; Elizabeth J Shpall; Anna S Lok
Journal:  Cancer       Date:  2017-05-18       Impact factor: 6.860

Review 10.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.